4basebio PLC

LSE 4BB.L

4basebio PLC Market Capitalization on January 14, 2025: USD 236.18 M

4basebio PLC Market Capitalization is USD 236.18 M on January 14, 2025, a 76.34% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

4basebio PLC 52-week high Market Capitalization is USD 357.97 M on June 18, 2024, which is 51.57% above the current Market Capitalization.
4basebio PLC 52-week low Market Capitalization is USD 126.37 M on January 22, 2024, which is -46.49% below the current Market Capitalization.
4basebio PLC average Market Capitalization for the last 52 weeks is USD 242.02 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

LSE: 4BB.L

4basebio PLC

CEO	Dr. Heikki Lanckriet Ph.D.
IPO Date	Feb. 17, 2021
Location	United Kingdom
Headquarters	25 Norman Way
Employees	101
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

4basebio PLC engages in the design, development, manufacturing, and supply of synthetic DNA and RNA products, and targeted non-viral vector solutions in the United States, Europe, and internationally. The company provides research kits, bulk enzymes, and other products, as well as licensing services; and AVV manufacturing services. It serves biotech, pharma, and contract development and manufacturing organization customers. The company was formerly known as 4basebio UK Societas and changed its name to 4basebio PLC in July 2021. 4basebio PLC was incorporated in 2020 and is based in Cambridge, United Kingdom.

Key trends

Past 5 years